Background. A novel translational pharmacology investigation was conducted by combining an in vitro efficacy target with mucosal tissue pharmacokinetic (PK) data and mathematical modeling to determine the number of doses required for effective human immunodeficiency virus (HIV) preexposure prophylaxis (PrEP)
Model systems which rapidly identify tissue drug concentrations protective of HIV infection could st...
Antiviral pre-exposure prophylaxis (PrEP) through daily drug administration can protect healthy indi...
Defining tissue and plasma-specific prophylactic drug concentrations is central to pre-exposure prop...
Background. A novel translational pharmacology investigation was conducted by combining an in vitro ...
The efficacy of HIV pre-exposure prophylaxis (PrEP) relies on adherence and may also depend on the r...
The efficacy of HIV pre-exposure prophylaxis (PrEP) relies on adherence and may also depend on the r...
The efficacy of HIV pre-exposure prophylaxis (PrEP) relies on adherence and may also depend on the r...
Background. This study estimated the number of daily tenofovir disoproxil fumarate/emtricitabine (TD...
A mainstay of strategies to prevent HIV-1 transmission is to use antiretroviral therapy (ART) for pr...
A mainstay of strategies to prevent HIV-1 transmission is to use antiretroviral therapy (ART) for pr...
Drug concentrations associated with protection from HIV-1 acquisition have not been determined. We e...
The use of antiretroviral medications in HIV-negative individuals as pre-exposure prophylaxis (PrEP)...
Introduction: More than a million people acquire HIV infection annually. Pre-exposure prophylaxis (P...
Model systems which rapidly identify tissue drug concentrations protective of HIV infection could st...
The early closure of a clinical trial assessing the effectiveness of oral antiretroviral pre-exposur...
Model systems which rapidly identify tissue drug concentrations protective of HIV infection could st...
Antiviral pre-exposure prophylaxis (PrEP) through daily drug administration can protect healthy indi...
Defining tissue and plasma-specific prophylactic drug concentrations is central to pre-exposure prop...
Background. A novel translational pharmacology investigation was conducted by combining an in vitro ...
The efficacy of HIV pre-exposure prophylaxis (PrEP) relies on adherence and may also depend on the r...
The efficacy of HIV pre-exposure prophylaxis (PrEP) relies on adherence and may also depend on the r...
The efficacy of HIV pre-exposure prophylaxis (PrEP) relies on adherence and may also depend on the r...
Background. This study estimated the number of daily tenofovir disoproxil fumarate/emtricitabine (TD...
A mainstay of strategies to prevent HIV-1 transmission is to use antiretroviral therapy (ART) for pr...
A mainstay of strategies to prevent HIV-1 transmission is to use antiretroviral therapy (ART) for pr...
Drug concentrations associated with protection from HIV-1 acquisition have not been determined. We e...
The use of antiretroviral medications in HIV-negative individuals as pre-exposure prophylaxis (PrEP)...
Introduction: More than a million people acquire HIV infection annually. Pre-exposure prophylaxis (P...
Model systems which rapidly identify tissue drug concentrations protective of HIV infection could st...
The early closure of a clinical trial assessing the effectiveness of oral antiretroviral pre-exposur...
Model systems which rapidly identify tissue drug concentrations protective of HIV infection could st...
Antiviral pre-exposure prophylaxis (PrEP) through daily drug administration can protect healthy indi...
Defining tissue and plasma-specific prophylactic drug concentrations is central to pre-exposure prop...